Form 8-K

8-K — Century Therapeutics, Inc.

Accession: 0001104659-26-071383

Filed: 2026-06-08

Period: 2026-06-08

CIK: 0001850119

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2617028d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2617028d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2617028d1_ex99-2.htm)

GRAPHIC (tm2617028d1_ex99-2img001.jpg)

GRAPHIC (tm2617028d1_ex99-2img002.jpg)

GRAPHIC (tm2617028d1_ex99-2img003.jpg)

GRAPHIC (tm2617028d1_ex99-2img004.jpg)

GRAPHIC (tm2617028d1_ex99-2img005.jpg)

GRAPHIC (tm2617028d1_ex99-2img006.jpg)

GRAPHIC (tm2617028d1_ex99-2img007.jpg)

GRAPHIC (tm2617028d1_ex99-2img008.jpg)

GRAPHIC (tm2617028d1_ex99-2img009.jpg)

GRAPHIC (tm2617028d1_ex99-2img010.jpg)

GRAPHIC (tm2617028d1_ex99-2img011.jpg)

GRAPHIC (tm2617028d1_ex99-2img012.jpg)

GRAPHIC (tm2617028d1_ex99-2img013.jpg)

GRAPHIC (tm2617028d1_ex99-2img014.jpg)

GRAPHIC (tm2617028d1_ex99-2img015.jpg)

GRAPHIC (tm2617028d1_ex99-2img016.jpg)

GRAPHIC (tm2617028d1_ex99-2img017.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2617028d1_8k.htm · Sequence: 1

false

0001850119

2026-06-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 8, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-40498

84-2040295

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

North 38th Street, 11th Floor

Philadelphia, Pennsylvania

19104

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name

of Exchange on Which Registered

Common Stock, par value $0.0001 per share

IPSC

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events

On June 8, 2026, Century Therapeutics, Inc. (the “Company”)

issued a press release announcing that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the

American Diabetes Association (ADA) 2026 Scientific Sessions (the “Conference”) being held June 5-8th in New

Orleans, Louisiana. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

A copy of the slides presented by the Company at the Conference is

filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no

obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

Document

99.1

Press Release of Century Therapeutics, Inc., dated June 8, 2026

99.2

American Diabetes Association (ADA) 2026 Scientific Sessions Presentation Slides of Century Therapeutics, Inc., dated June 8, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By:

/s/

Brent Pfeiffenberger, Pharm.D.

Name:

Brent Pfeiffenberger, Pharm.D.

Title:

President, Chief Executive

Officer and Chairman of the Board of Directors

Date: June 8, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2617028d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

New CNTY-813 Preclinical Data Demonstrate Durable

Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

· Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes

· CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months

in preclinical models

· Allo-Evasion™ 5.0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse

model without immunosuppression

· Phase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optimal islet cell content

· CNTY-813 IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027

PHILADELPHIA, June 8, 2026 - Century Therapeutics, Inc.

(‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies

for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813,

Century’s iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0, in an oral presentation at the American

Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, Louisiana.

T1D affects approximately nine million people worldwide. While islet

cell transplantation has demonstrated the potential to restore insulin independence, with insulin independence achieved in approximately

70% of patients receiving cadaveric islet transplantation at one year, the current approach requires chronic systemic immunosuppression.

The need for chronic immunosuppression limits the utility of cell transplantation for the majority of T1D patients. CNTY-813 is designed

to address this directly: a potential off-the-shelf, iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0 to

eliminate the need for immunosuppression and exogenous insulin. Based on preclinical data to date, Century believes CNTY-813 has the potential

to deliver what no prior therapy has achieved, a functional cure for T1D without the need for chronic immunosuppression.

The presentation, titled “CNTY-813: Scalable Production of Allo-Evasion™

5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies” (Abstract 1318-OR), was delivered by Leonardo Velazco-Cruz, Ph.D.,

at 2:45 p.m. CT. The data highlight CNTY-813’s demonstrated functional potency, scalable manufacturing, engraftment with no

evidence of abnormal outgrowth or tumorigenesis, and ability to maintain glucose control under allogeneic immune pressure, a combination

of properties that Century believes distinguishes CNTY-813 as a completely novel approach to islet cell replacement.

"These preclinical data advance our case for a potentially functional

cure for type 1 diabetes. Across a range of preclinical studies, CNTY-813 has now demonstrated what we believe are critical prerequisites

for a potentially curative islet replacement therapy: glucose-responsive function comparable to primary islets, graft stability with no

evidence of tumorigenesis, and immune evasion engineered to eliminate the need for chronic immunosuppression," said Brent Pfeiffenberger,

Pharm.D., Chief Executive Officer of Century Therapeutics. "Having established our Phase 1 manufacturing process and demonstrated

consistent product quality across independent batches, we are confident in our readiness for clinical trials and the potential to scale

for broad patient access. With our IND submission on track for the fourth quarter of 2026 and initial clinical data anticipated in the

second half of 2027, we are executing with discipline toward what we believe is a highly competitive and differentiated program.”

Preclinical data highlights

The oral presentation highlighted new preclinical data from CNTY-813

studies as outlined below. The full presentation is available on the Presentations tab of Century’s investor relations website

at investors.centurytx.com/events-and-presentations.

Durable glucose control in vivo

CNTY-813 iPSC-derived islet cells rapidly restored normoglycemia in

streptozotocin-rendered diabetic mice and maintained glucose control for greater than eight months following transplantation. New data

demonstrate that Allo-Evasion™ 5.0-edited cells showed comparable glucose control to non-edited cells, confirming the immune evasion

engineering modifications do not affect the islets’ ability to control glucose. Islet performance in a glucose tolerance test demonstrated

glucose normalization within 60 minutes in both edited and unedited islets.

Cell composition and acceptable post-mitotic safety profile

New single-cell RNA sequencing analysis demonstrated that CNTY-813

contains a consistent and optimal ratio of differentiated cell types in islet clusters, with beta cells comprising greater than 50% of

total cell composition. Greater than 98% of cells were identified in G1 phase, indicating cell cycle exit on par with primary islets.

In vivo graft analysis at two, four, and eight weeks post-infusion confirmed endocrine graft morphology was maintained with no evidence

of cyst formation or abnormal outgrowth, as assessed by Ki67 staining over time. No tumorigenesis was observed in more than 140 mice with

more than three months of follow-up across one billion cells infused.

Immune evasion: in vitro protection

Additional data from multiple in vitro assays demonstrated that CNTY-813

cells containing Allo-Evasion™ 5.0 edits provided significant protection from natural killer (NK) cell clearance, induced rapid

IgG cleavage of a surrogate anti-drug antibody, and demonstrated protection from antibody-mediated phagocytosis. These results confirm

functional activity across all three engineered immune protection layers: T cells, NK cells, and humoral evasion.

Immune evasion: in vivo protection in humanized mouse model

New data from a humanized mouse allogeneic graft rejection model engrafted

with healthy donor peripheral blood mononuclear cells (PBMCs) to support survival of functional human T cells without graft-versus-host

disease and human NK cells, demonstrated that mice transplanted with CNTY-813 maintained normal C-peptide secretion function through 42

days post-transplant. In contrast, mice transplanted with unedited islet grafts showed rapid functional deterioration and allo-rejection

with PBMC co-engraftment. Consistent with immune evasion, Allo-Evasion™ 5.0-engineered islets maintained glucose tolerance in a

glucose tolerance test under allogeneic immune pressure while unedited islets showed reduced function.

Consistent product quality from Phase 1 clinical manufacturing process

Century has established its manufacturing processes for Phase 1 clinical

trial supply. New data demonstrated consistent product quality across three separate at-scale experiments from Century’s GMP Master

Cell Bank, comprising 11 samples, with optimal endocrine purity, islet cell content, and minimal islet cell impurities across all samples.

The 29-day, bioreactor-based suspension differentiation process met pre-defined purity specifications at each stage. The process supports

cryopreservation with retained post-thaw potency.

Upcoming CNTY-813 milestones

· IND submission (4Q 2026): Century expects to submit an Investigational New Drug application for CNTY-813 in the fourth quarter

of 2026, subject to completion of remaining IND-enabling studies.

· Initial clinical data (2H 2027): Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated

in the second half of 2027.

About CNTY-813

CNTY-813 is Century’s potential iPSC-derived islet replacement

therapy for T1D. CNTY-813 is engineered with Allo-Evasion™ 5.0, Century’s proprietary immune evasion technology, which is

designed to enable durable engraftment without chronic systemic immunosuppression, the central unresolved limitation of every currently

approved or late-stage cell therapy approach to T1D. Preclinical data demonstrated robust glucose-responsive function, favorable pre-clinical

safety profile, scalable and reproducible manufacturing, and immune protection under alloimmune pressure. Century is targeting an IND

submission for CNTY-813 in the fourth quarter of 2026.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing

a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases,

including type 1 diabetes, and cancer. Century’s therapies are derived from its iPSC cell foundry and leverage its novel immune

evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand

patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information

on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning

of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained

in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including

but not limited to, statements about our timing and expectations regarding our preclinical and clinical development programs, including

planned development of CNTY-813, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions,

the achievement of developmental milestones, corporate strategies, and anticipated data readouts, are forward-looking statements. These

statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance,

or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking

statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,”

“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”

“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”

“predict,” “forecast,” “potential” or “continue” or the negative of these terms or other

similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements

largely on our current expectations and projections about future events and financial trends that we believe may affect our business,

financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are

subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond

our control, including, among others: our ability to successfully advance our current and future product candidates through development

activities, preclinical studies, and clinical trials; our ability to meet development milestones on anticipated timelines; uncertainties

inherent in the results of preliminary data, and pre-clinical studies , which may not be predictive of final results or the results of

clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected

timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development

of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of

our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business

and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates,

including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully

commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability

to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property

protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent

filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements

as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur,

and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry

and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk

factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking

statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For more information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

LifeSci Advisors, LLC

Corey Davis, Ph.D.

212-915-2577

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2617028d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

CNTY-813:

Scalable Production of Allo-Evasion 5.0-

Engineered iPSC Islets for Off-the-Shelf

Cell Therapies

Leonardo Velazco-Cruz, PhD

• Presenter

– Leonardo Velazco-Cruz, PhD

• Relevant Financial Relationship

– Employee, Century Therapeutics

– Stock/Shareholder: Century Therapeutics

• Presentation Information:

– This presentation describes preclinical research related to CNTY-813, an investigational iPSC-derived islet

cell therapy for T1D

– The content is intended for scientific and educational discussion

– No clinical recommendations will be made

Disclosures

Forward-looking statements

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995.

All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,

statements regarding our clinical development plans and timelines and the initial safety and efficacy profiles of CNTY-813 and statements regarding our preclinical development

programs, including initial preclinical data and development plans and timelines are forward-looking statements. These statements involve known and unknown risks, uncertainties

and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed

or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,”

“seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other

similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and

projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak

only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are

beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and

clinical trials; our ability to progress CNTY-813 through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results

of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain

clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative

relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval

of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force;

the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and

manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to

recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and

uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should

not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur,

and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and

uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law,

we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or

otherwise.

Islet cell transplantation provides potential for curative therapy in T1D

In T1D, beta cells are destroyed

Healthy beta cells

produce insulin (green)

In T1D, beta cells are

destroyed

Insulin independence following pancreatic islet transplantation

1. Approximately 1500 patients reported in https://www.citregistry.org/system/files/CITR%2012th%20Allograft%20Report_2025_Final.pdf

Islet transplantation provides a potentially curative therapy for T1D

Insulin independence achieved for one year in ~70% of patients receiving allogenic

cadaveric islet transplantation1

Source: Marfil-Garza et al. 2022; Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada

Supply and chronic immunosuppression limit the broader use of

T1D cell therapies

CNTY-813: Century’s islets with Allo-Evasion 5.0 are designed to address key challenges in T1D cell therapy

Scalable manufacturing, islet function, and immune-evasive engineering address key barriers for T1D cell replacement

DIFFERENTIATION

PLATFORM

• Scalable iPSC-derived islet

manufacturing

• Reproducible islet

differentiation

• Clinical manufacturing process

from GMP MCB

CNTY-813 design integrates key capabilities for off-the-shelf T1D cell therapy

FUNCTIONAL

ISLETS

• Glucose-responsive insulin

secretion

• In vivo glucose control in

diabetic mice

• No safety events observed to

date in preclinical models

– i.e., cyst or tumor formation

ALLO-EVASION

5.0

• T cell protection

• NK cell protection

• Reduced humoral immune

clearance

• Dotted lines: success criteria

• N are independent batches.

• Source: Company data on file

Defined, Multi-stage Bioreactor Enabled Differentiation Process

Adapted to a Scalable Bioreactor Suspension System

iPSC Definitive

Endoderm

Primitive

Gut Tube

Pancreatic

Progenitor

Pancreatic

Progenitor

Endocrine β Cell

Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6

Consistent Differentiation

• Surpassed the necessary purity at

every stage

• >95% Endocrine

• 50-60% Beta Cells (Insulin Producing)

Stage 1:

Definitive Endoderm

Stage 4:

Pancreatic Progenitor II

Stage 6:

Islet Endocrine

Stage 6:

Beta Cell

Mean (n) 97.3 (20) 98.2 (24) 95.9 (32) 60.2 (32)

4X 300um

CONFIDENTIAL

Endocrine Purity Beta Cell Content Islet Cell Impurity

• 3 Batches

• 11 Samples

Phase 1 clinical manufacturing process established and executed from MCB

across 3 independent batches

MCB Thaw → iPSC Expansion → Bioreactor Differentiation → Cryopreserved Intermediate → Post-Thaw Maturation → Final Fresh Product

Consistent final product flow cytometry profiles across 3 at-scale batches

Source: Company data on file

CNTY-813 islet cells demonstrate robust glucose-responsive function

Potency

Glucose Stimulated Insulin Secretion Stimulation Index Total Insulin Content

iPSC- Islets

Primary Islets

Glucose Stimualtion Index

(20mM glucose/ 2mM glucose)

Mean +/- SD is shown in graphs

iPSC- Islets Primary Islets

10000

20000

30000

40000

u UI Insulin/ 1E6 Cells

2mM Glucose

20mM Glucose

Source: Company data on file

∆GSIS

CNTY-813 islets rapidly restored normoglycemia in STZ-induced diabetic mice

Allo-Evasion 5.0-edited CNTY-813 restored glucose control comparable to unedited islets and persists for >8 months

Potency

Non-Fasted Blood Glucose

STZ = Streptozotocin | SRC = Sub renal capsule implantation, Gray shaded area = normal blood glucose range

125

150

175

2 5

250

275

100

200

300

400

500

600

Days Post Treatment

Blood Glucose m( g/dL)

No Treatment Normoglycemia Control

CNTY-813 (SRC)

(5M)

Unedited CNTY Islet Cells

(5M)

0 20 40 60 80 100 120

100

200

300

400

500

600

Time (min)

Blood Glucose (mg/dL)

Diabetic Control Unedited CNTY Islet Cells

(5M) CNTY-813 (SRC)

(5M)

Glucose

Control

Glucose

Control

Glucose Tolerance Test

Source: Company data on file

Mean +/- SEM Mean +/- SD

CNTY-813 islets contain defined endocrine cell populations

Population (30,151 total) Frequency

β cells: 66.3%

FEV+ Islet Cells 26.4%

⍺ cells 5.5%

δ cells 0.8%

Exocrine/Ductal 1.0%

CNTY-813 data represents four combined end-of-process samples Population Enriched Markers: β-cell: INS, NKX6.1; ⍺-cell: GCG,ARX; δ-cell: SST; Exocrine/Ductal: KRT19; FEV+ Islet Cell: FEV+SLC18A1+

scRNAseq Cell Cycle Annotations

Diff. Stage: iPSC 1 2 3 4 5 6

scRNAseq Cell Type Annotations

• CNTY-813 achieves a defined islet endocrine composition, with beta cells as the predominant population

• Data is consistent with cell cycle exit on par with primary islets by end of manufacture (>98% G1 phase identity)

CNTY-813 grafts maintain endocrine identity with no evidence of tumorigenesis

2 weeks

INS+ (green)

CHGA+ (orange)

Merged (yellow)

4 weeks 8 weeks

Ki67+ (pinK)

DAPI (blue)

Endocrine graft identity over time

✓ Endocrine graft morphology maintained through 8 weeks

✓ No Ki67 increase or cyst formation was observed through

8 weeks

✓ No tumorigenesis observed in >140 mice with >3-month

follow up (>1B cells infused)

Quantification of Ki67+ over time

Ki67 staining includes host-derived cells; not human specific.

INS: Insulin stain; CHGA: CHGA stain; Ki67: Stain for Ki67; DAPI: nuclear stain 200µm

Source: Company data on file

CNTY-813 is engineered to evade T cell, NK cell, and humoral responses

Protection from:

T cells

NK cells

Humoral

Immunity

Deletion of HLA-I

Deletion of HLA-II

Insertion of CD300a TASR pan-NK

inhibitory ligand1, 2

Insertion of cell-surface enzyme to

degrade IgG antibodies3

1. https://www.centurytx.com/wp-content/uploads/ASH_Welstead_Universal-Protection-of-Allogenic-T-Cells-Final.pdf

2. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013436/518079/Universal-Protection-of-Allogeneic-T-Cell

3. Peraro et al, Mol. Therapy 2021, 29(12), 3398-3409; https://pmc.ncbi.nlm.nih.gov/articles/PMC8636170

b2M KO (HLA-I)

CIITA

KO (HLA-II)

CD8+

T Cell

CD4+

T Cell

Pan NK Inhibitory

ligand

NK cell

No HLA-I

Prevents recognition

by CD8+ cells T cells

No HLA-II

Prevents recognition

by CD4+ cells T cells

IgG Cleavage

Reduces Fc binding

and humoral activity

CD300a TASR Ligand

Inhibits NK cell

activation

ALLO-EVASION 5.0

CNTY-813 demonstrated protection from multiple immune effector mechanisms

1. NK-CELL PROTECTION 2. IgG CLEAVAGE 3. PROTECTED FROM PHAGOCYTOSIS

Reduced NK Cell Activation

Reduced NK Cell Cytotoxicity

Rapid IgG Cleavage Reduced Antibody-Dependent

Phagocytosis (ADCP)

Significant reduction in intact IgG

after 1 hour in cleavage assay

CNTY-813 did not activate or get

cleared by NK cells

CNTY-813 degraded IgG

antibodies in vitro

CNTY-813 protection from

Ab-mediated phagocytosis

Protection from ADCP achieved against

an antibody targeting EpCAM

0.25:1 0.5:1 1:1 2:1

E:T ratio

CD107a+ (%)

WT DKO

CTNY-813

****

**** **** ****

Activation

Source: Company data on file

*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001

Donor 1 Donor 2

100

125

NK Cell Donor

Percent Survival (%)

DKO

CNTY-813

✱✱✱ ✱✱✱

Employing a humanized mouse model to study allogeneic graft rejection

Humanized Mouse Engrafted with Healthy Donor PBMCs

• Functional human T cells without GvHD (MHC DKO) – supports

longer study durations

• Supports engraftment and survival of human NK cells

(TgHu-IL15)

• Testing of allo-rejection mediated by human T cells and NK cells

(huPBMCs)

NSG-MHC I/II DKO+/+ NSG-Tg(Hu-IL15)+/+

No GvHD Human NK

cell support

Human immune-cell engraftment supports functional testing of allo-rejection in vivo

Allo-evasion 5.0 maintains CNTY-813 Glucose Stimulated Insulin Secretion

Allo-Evasion 5.0 protected CNTY-813 from rejection in humanized mice

0 7 14 21 28 35 42 49

Days Post Transplant Glucose-Stimulated Insulin Secretion Index

(C-peptide induction over baseline) Unedited Islets + PBMCs Unedited Islets

0 7 14 21 28 35 42 49

Days Post Transplant Glucose-Stimulated Insulin Secretion Index

(C-peptide induction over baseline) CNTY-813 Allo-Evasion 5.0 Islets + PBMCs CNTY-813 Allo-Evasion 5.0 Islets

Glucose Stimulation Index

Mean ± SEM

Allo-Rejection

Reduced function with

PBMC engraftment

Maintained function with

PBMC engraftment

Unedited Islets

Allo-Evasion 5.0 Islets

Readout

Human C-peptide stimulation

index (over-baseline)

Interpretation

Higher response indicates

preserved graft insulin

secretion

C-Peptide is a surrogate for insulin

Source: Company data on file

Allo-evasion 5.0 maintained CNTY-813 GTT performance

0 30 60 90 120

200

400

600

Time (min.)

Blood Glucose (mg/dL)

Unedited Islets + PBMCs Unedited Islets

0 30 60 90 120

200

400

600

Time (min.)

Blood Glucose (mg/dL)

Allo-Evasion 5.0 Islets + PBMCs Allo-Evasion 5.0 Islets

Glucose Tolerance Test (GTT)

Unedited Islets

Allo-Evasion 5.0 Islets

(11 weeks post-islet infusion)

Mean ± SD

Readout

Human blood glucose as

depicted by area under the

curve (AUC) during glucose

tolerance test

Interpretation

Lower AUC indicates faster

glucose clearance and better

glucose control

Allo-Evasion 5.0 protected CNTY-813 from rejection in a humanized mouse

Reduced function with

PBMC engraftment

Maintained function with

PBMC engraftment

Source: Company data on file

These data support the development of CNTY-813 as a potentially broadly accessible off-the-shelf cell therapy for Type 1 Diabetes

DIFFERENTIATION

PLATFORM

• Reproducible, bioreactor-enabled differentiation from

GMP MCB

• Phase 1 clinical manufacturing

process established

• CNTY-813 specs:

– >95% islet endocrine

– >50% beta cell identity

CNTY-813 demonstrated reproducible differentiation, durable glucose control,

and immune-evasive function in preclinical models

FUNCTIONAL

ISLETS

• GSIS potency similar to primary

islets

• Rapid and durable glucose

control observed in diabetic

mice

• Maintained graft identity with a

favorable safety profile

ALLO-EVASION

5.0

• Engineered to reduce T-cell, NK-cell, and humoral immune

recognition

• Protection from NK and

humoral clearance

demonstrated

• Preserved graft function under

alloimmune pressure in vivo

GRAPHIC

Filename: tm2617028d1_ex99-2img001.jpg · Sequence: 7

Binary file (163595 bytes)

Download tm2617028d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img002.jpg · Sequence: 8

Binary file (102836 bytes)

Download tm2617028d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img003.jpg · Sequence: 9

Binary file (356321 bytes)

Download tm2617028d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img004.jpg · Sequence: 10

Binary file (194897 bytes)

Download tm2617028d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img005.jpg · Sequence: 11

Binary file (154712 bytes)

Download tm2617028d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img006.jpg · Sequence: 12

Binary file (140587 bytes)

Download tm2617028d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img007.jpg · Sequence: 13

Binary file (148344 bytes)

Download tm2617028d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img008.jpg · Sequence: 14

Binary file (103560 bytes)

Download tm2617028d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img009.jpg · Sequence: 15

Binary file (151960 bytes)

Download tm2617028d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img010.jpg · Sequence: 16

Binary file (146397 bytes)

Download tm2617028d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img011.jpg · Sequence: 17

Binary file (193386 bytes)

Download tm2617028d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img012.jpg · Sequence: 18

Binary file (127143 bytes)

Download tm2617028d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img013.jpg · Sequence: 19

Binary file (166647 bytes)

Download tm2617028d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img014.jpg · Sequence: 20

Binary file (145080 bytes)

Download tm2617028d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img015.jpg · Sequence: 21

Binary file (139837 bytes)

Download tm2617028d1_ex99-2img015.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img016.jpg · Sequence: 22

Binary file (143354 bytes)

Download tm2617028d1_ex99-2img016.jpg

GRAPHIC

Filename: tm2617028d1_ex99-2img017.jpg · Sequence: 23

Binary file (196926 bytes)

Download tm2617028d1_ex99-2img017.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 25

v3.26.1

Cover

Jun. 08, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 08, 2026

Entity File Number

001-40498

Entity Registrant Name

Century Therapeutics, Inc.

Entity Central Index Key

0001850119

Entity Tax Identification Number

84-2040295

Entity Incorporation, State or Country Code

Entity Address, Address Line One

North 38th Street

Entity Address, Address Line Two

11th Floor

Entity Address, City or Town

Philadelphia

Entity Address, State or Province

Entity Address, Postal Zip Code

19104

City Area Code

267

Local Phone Number

817-5790

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

IPSC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration